Actelis amends 8-K to state offering proceeds for general corporate purposes

ACTELIS NETWORKS INC

Amendment revises prior 8-K (Dec 17, 2025); proceeds now for general corporate purposes not R&D.
Original 8-K stated proceeds intended for pre-clinical/clinical studies; amended to match press release.
No other changes to the original 8-K or its exhibits; filing date December 22, 2025.
Company ticker ASNS; CEO Tuvia Barlev signed the amendment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.